Drug Type Small molecule drug |
Synonyms 2,8-Diaminoacridine, Proflavine hemisulfate |
Target |
Action- |
Mechanism DNA intercalators |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization- |
Active Organization |
License Organization- |
Drug Highest PhaseClinical |
First Approval Date- |
Regulation- |
Molecular FormulaC13H11N3 |
InChIKeyWDVSHHCDHLJJJR-UHFFFAOYSA-N |
CAS Registry92-62-6 |
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | Proflavine | - |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Esophageal Squamous Cell Carcinoma | Phase 2 | United States | 31 Jan 2014 | |
| Esophageal Squamous Cell Carcinoma | Phase 2 | China | 31 Jan 2014 | |
| Adenocarcinoma of Esophagus | Phase 2 | United States | 30 Sep 2012 | |
| Barrett Esophagus | Phase 2 | United States | 30 Sep 2012 | |
| Endocarditis, Bacterial | Phase 2 | United States | 30 Sep 2012 | |
| Carcinoma | Phase 1 | United States | 25 May 2016 | |
| Muscular Dystrophy, Oculopharyngeal | Phase 1 | United States | 25 May 2016 | |
| Uterine Cervical Cancer | Phase 1 | United States | 23 Sep 2015 | |
| Uterine Cervical Dysplasia | Phase 1 | United States | 23 Sep 2015 | |
| Helicobacter pylori infection | Phase 1 | United States | 31 Jan 2015 |
Not Applicable | 9 | High-Resolution Microendoscopy (HRME) Imaging+Proflavine | nusccwpjgc(feqngyqmhs) = bcjvemqoou pdjuabwefl (hgemldqkih, nuapeioyuw - nkgzfgbvcv) View more | - | 25 Jul 2022 |





